China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences
This article was originally published in PharmAsia News
Executive Summary
Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.
You may also be interested in...
Challenging Lucentis: Eylea’s Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012
Eylea manufacturer Regeneron says the new treatment for wet AMD is being reimbursed by all regional Medicare claims contractors.
Jiangsu Hengrui Shifts From Generic Supplier To Innovative Company; Analysts See Shades Of Takeda In Transformation
SHANGHAI - Jiangsu Hengrui Medicine Co. Ltd. seeks to transform itself from a generic company to an innovative one and tap into overseas markets. The move has prompted Chinese analysts to draw comparisons to the business models of Japan's largest pharma and to predict that Jiangsu Hengrui could become China's version of Takeda Pharmaceutical Co. Ltd.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.